Graphene & NanoCoatings Market 2020 Global Forecasts


By RnR Market Research

Published: Tuesday, Sep. 17, 2013 – 1:58 pm

DALLAS, Sept. 17, 2013 — /PRNewswire-iReach/ — NanoCoatings: The Global Market to 2020 and Graphene: The Global Market to 2020 are the new industry research reports available with Presented in a graphical format, the fully updated nanocoatings market report provides an easily readable and succinct guide to nanocoatings, their applications and markets thereof. In the coating sector, high transparency, new functionalities and high-quality performance are increasingly important requirements and nanomaterials are being increasingly exploited to meet these needs. Nanostructured coatings and films are witnessing growth in industries such as oil and gas, construction, solar, glass and electronics as they offer significant performance advantages over traditional coatings as well as being more potentially more cost-effective and environmentally friendly.

Read more

Graphene: The Global Market To 2020 | Market Shares, Size, Trend, Analysis, and Forecasts to 2020

graphene investment

Albany, NewYork (PRWEB) September 08, 2013

Graphene Market report is designed for clients needing a quality in-depth understanding of the Chemicals for Graphene Market report. These reports provide a much more granular and detailed data set than our competitors. All data have been researched, brand upwards, by an experienced ”on-the-ground” industry analyst who conducts face-to-face interviews with key producers, leading companies in allied industries, distributors and retailers.

Read more

Grafoid Inc. and ProScan Rx Pharma Inc. Establish Calevia Inc. to Develop Graphene-based, Non-Invasive Cancer Eradication Therapies



OTTAWA — (Marketwire – September 5, 2013) – Grafoid Inc. announced today the formation of Calevia Inc., a joint venture partnership with ProScan RX Pharma Inc. to develop an entirely new graphene-based nanotechnology platform for the precise targeting and thermal eradication of solid cancer tumors.

Grafoid President and CEO Gary Economo said Calevia’s unique targeted photothermal therapy aims to overcome the side effects and strong limitations of common cancer therapies such as surgery, radiation and chemotherapy.

Read more